Pharvaris reports positive topline CHAPTER-3 data for deucrictibant XR
Pharvaris says its CHAPTER-3 pivotal study of deucrictibant XR for prophylaxis of hereditary angioedema (HAE) attacks produced positive topline data, per the company announcement.
ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris NASDAQ:PHVS, a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of people living with bradykinin-mediated angioedema (AE-BK), including hereditary angioedema (HAE) a…